Last updated on April 2020

ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Therapies (TIDAL)


Brief description of study

This is the study of the PI3K inhibitor ME-401 in subjects with relapsed/refractory follicular lymphoma after failure of at least 2 prior lines of systemic therapy

Detailed Study Description

This is a global, multicenter open-label, single-arm, Phase 2 study of the PI3K inhibitor ME-401 in subjects with relapsed/refractory follicular lymphoma after failure of at least 2 prior lines of systemic therapy which must have included an anti-CD20 antibody and chemotherapy with an alkylating agent or a purine analogue.

Approximately 120 subjects will be enrolled and treated with ME-401 on the intermittent schedule.

Clinical Study Identifier: NCT03768505

Find a site near you

Start Over